Section 3, Lecture 2

Size: px
Start display at page:

Download "Section 3, Lecture 2"

Transcription

1 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect against osteoporosis Loop diuretics -used in patients with poor kidney function where thiazide derivatives will not be effective 1

2 vasodilators β-antagonists α-antagonists Angiotensin II receptor antagonists β-antagonists β- antagonists CNS-directed sympatholytics ACE inhibitors Angiotensin II receptor antagonists diuretics 2

3 Potassium-Sparing Diuretics -mild diuretic and antihypertensive effect -Minimize renal-k + loss thus preventing hypokalemia -If the patient can t tolerate these drugs then use thiazide and take KCl tablets Drug Classification Diuretics Thiazide and loop diuretics Common Adverse Effects Blood cell deficiencies, hyperlipidemia, hyperuricemia, hypokalemia, and other electrolyte changes Aggravation of diabetes Common Drug Interactions Increase serum levels of lithium. Hypotensive effect decreased by NSAIDs and augmented by ACE inhibitors Potassium-sparing diuretics Hyperkalemia Hyperkalemic effect increased by ACE inhibitors and potassium supplements 3

4 Sympatholytics Drug Classification Adrenergic receptor antagonists α-adrenergic receptor antagonists β-adrenergic receptor antagonists Centrally acting drugs Clonidine Guanabenz Guanfacine Methyldopa Common Adverse Effects Dizziness, first-dose syncope, fluid retention, and orthostatic hypotension Bradycardia, bronchoconstriction, depression, fatigue, impaired glycogenolysis, and vivid dreams Dry mouth, fatigue, rebound hypertension, and sedation Same as clonidine Same as clonidine but milder Autoimmune hemolytic anemia, hepatitis, and lupuslike syndrome. Other adverse effects same as those of clonidine Common Drug Interactions Hypotensive effect increased by β-adrenergic receptor antagonists and diuretics Cardiac depression increased by diltiazem and verapamil. Hypotensive effect decreased by NSAIDs Hypotensive effect decreased by tricyclic antidepressants Sedative effect increased by CNS depressants Same as clonidine Same as clonidine Hypotensive effect increased by levodopa. Other interactions same as those of clonidine 4

5 vasodilators β-antagonists α-antagonists Angiotensin II receptor antagonists β-antagonists β- antagonists CNS-directed sympatholytics ACE inhibitors Angiotensin II receptor antagonists diuretics 5

6 Angiotensin Inhibitors Drug Oral Bioavailabili ty Absorption Reduced by Food Active Metabolite Duration of Action (Hours) Angiotensin-converting enzyme inhibitors Benazepril 37% No Benazeprilat Captopril 75% 30-40% None 12-Jun Enalapril 60% No Enalaprilat* Fosinopril 36% No Fosinoprilat Lisinopril 25% No None Quinapril 60% 25-30% Quinaprilat Ramipril 55% No Ramiprilat Angiotensin receptor antagonists Losartan 33% 10% Carboxylic acid metabolite Valsartan 25% 40% None Candesartan 15% No None 6

7 Angiotensin inhibitors 1. ACE inhibitors 2. Angiotensin receptor inhibitors Renin secretion induced by: 1-Symp. Outflow 2-reduction in BP and wall tension in renal arterioles 3-reduced NaCl reabsorbtion AT 1 AT 1 G-proteins IP3 7

8 ACE inhibitors Adverse effects Increase fetal morbidity and mortality, especially during 2 nd and 3th trimesters Renal failure in patients with bilateral renal artery stenosis 8

9 Drug Classification Angiotensin inhibitors Common Adverse Effects Common Drug Interactions Angiotensin-converting enzyme (ACE) inhibitors Angiotensin receptor antagonists Acute renal failure, angioedema, cough, hyperkalemia, loss of taste, neutropenia, and rash Hyperkalemia Increase serum levels of lithium. Hyperkalemic effect increased by potassiumsparing diuretics and potassium supplements. Hypotensive effect decreased by NSAIDs Serum levels of drug increased by cimetidine and decreased by phenobarbital 9

10 Vasodilators Organic nitrites and nitrates Amyl nitrites; (nitrites), administered by inhalation Nitroglycerin (glyceryl trinitrate); sublingual, oral or transdermal administration Calcium channel blockers Amlodipine, felodipine Diltiazem, verapamil 10

11 Tolerance Aldehyde dehydrogenase releases NO from nitroglycerin, and this process is accompanied with formation of superoxide anion free radical (O 2 - ) that in turn, deactivate aldehyde dehydrogenase -to avoid periodically interrupt the administration of the drugs Pills sublingual Sustained release- patches, skin ointments, IV Adverse effects- headaches, hypotension, dizziness, reflex tachycardia, use β-blocker in combination 11

12 Ca 2+ - channel blockers (CCBs) Suppress cardiac activity and relax smooth muscles-in combination increase coronary blood flow Side effects: fatigue, headache, dizziness, flushing, peripheral edema Occasionally cause gingival hyperplasia 12

13 Selection of Antihypertensive Drugs for Patients with Specific Traits or Concurrent Diseases Patient Characteristic Age over 65 years African heritage Pregnant Angina pectoris Myocardial infarction Congestive heart failure Recurrent stroke prevention Chronic kidney disease Diabetes Asthma Benign prostatic hyperplasia Migraine headache Osteoporosis Most Preferred Drugs Diuretic, ACEI, CCB Diuretic, CCB Methyldopa, labetalol β-blocker, CCB β-blocker, ACEI, aldosterone antagonist Diuretic, ACEI, ARB, β-blocker Diuretic, ACEI, ARB ACEI, ARB Diuretic, ACEI, ARB, β-blocker, CCB CCB, ACEI α-blocker β-blocker, CCB Diuretic Least Preferred Drugs Centrally acting α2 agonist β-blocker ACEI, ARB Hydralazine, minoxidil β-blocker 13

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys

More information

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Antihypertensive drugs SUMMARY Made by: Lama Shatat Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone

More information

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit

More information

sympatholytics sympatholytics sympatholytics

sympatholytics sympatholytics sympatholytics sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors

More information

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015 Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor

More information

Introduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP

Introduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP Introduction Hypertension is a persistent elevation of blood pressure above 140 / 90 mmhg for more than three sitting. (0ptimal level

More information

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Antihypertensive Agents

Antihypertensive Agents Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,

More information

Beta 1 Beta blockers A - Propranolol,

Beta 1 Beta blockers A - Propranolol, Pharma Lecture 3 Beta blockers that we are most interested in are the ones that target Beta 1 receptors. Beta blockers A - Propranolol, it s a non-selective competitive antagonist of beta 1 and beta 2

More information

DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI

DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI 3. Vasodilators Drugs which dilate blood vessels ( decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:

More information

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias 1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should

More information

Antihypertensive drugs: I. Thiazide and other diuretics:

Antihypertensive drugs: I. Thiazide and other diuretics: Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications

More information

What in the World is Functional Medicine?

What in the World is Functional Medicine? What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They

More information

HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg

HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between

More information

Treatment of Essential Hypertension

Treatment of Essential Hypertension 2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology

More information

Hypertension Management - Summary

Hypertension Management - Summary Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)

More information

Antihypertensives. Diagnostic category

Antihypertensives. Diagnostic category Measurement of blood pressure At first assessment, take both arms then choose the one with the higher reading. Beware of orthostatic hypotension. Measure BP in sitting position, and repeat after patient

More information

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances

More information

University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D

University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D Cardiovascular Pharmacology 1. Antihypertensives 2. Antianginal 3. Drugs for HF 4. Antiarrythemics 5. Drugs for Hyperlipoproteniemia

More information

Antihypertensive Drugs. Nafrialdi

Antihypertensive Drugs. Nafrialdi Antihypertensive Drugs Nafrialdi 1 Mechanisms of Blood Pressure Regulation Blood Presure Cardiac Output Peripheral Resistance Heart Rate Stroke volume Vascular tone Vessel elasticity Myocardial contractility

More information

Treatment of Essential Hypertension

Treatment of Essential Hypertension 2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy

More information

Antihypertensive Agents

Antihypertensive Agents Antihypertensive Agents Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 13.11.2009 1 Süzer Farmakoloji 3. Baskı 2005 2 1 Süzer Farmakoloji 3. Baskı 2005 3 Süzer Farmakoloji 3. Baskı 2005

More information

Hypertension. Penny Mosley MRPharmS

Hypertension. Penny Mosley MRPharmS Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines

More information

ANTIHYPERTENSIVE AGENTS AND VASODILATORS. Lecture 5

ANTIHYPERTENSIVE AGENTS AND VASODILATORS. Lecture 5 ANTIHYPERTENSIVE AGENTS AND VASODILATORS Lecture 5 Hypertension Blood pressure BP = CO x PVR n Interaction between autonomic nervous system, cardiovascular system and renal system Normal: 110/70 Prehypertension

More information

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic

More information

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood

More information

Prof dr Aleksandar Raskovic DIRECT VASODILATORS

Prof dr Aleksandar Raskovic DIRECT VASODILATORS Prof dr Aleksandar Raskovic DIRECT VASODILATORS Direct vasodilators Minoxidil (one of the most powerful peripheral arterial dilators) Opening of KATP channels, efflux of K, lose of Ca and smooth muscle

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Antihypertensive Agents

Antihypertensive Agents 1. Blood Pressure Regulation Antihypertensive Agents - 2007 Edward JN Ishac. Ph.D. Associate Professor, Dept. Pharmacology & Toxicology Office: Smith 742; Tel: 828 2127 eishac@hsc.vcu.edu Frank's formula,

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle

More information

Chapter 2 ~ Cardiovascular system

Chapter 2 ~ Cardiovascular system Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection

More information

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR

More information

1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril.

1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril. SUMMARY 1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril. 2. While diuretics and beta-blockers remain first-line antihypertensive

More information

Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.

Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris. Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.

More information

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension

More information

Guideline-Directed Medical Therapy

Guideline-Directed Medical Therapy Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in

More information

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Byvalson. (nebivolol, valsartan) New Product Slideshow

Byvalson. (nebivolol, valsartan) New Product Slideshow Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength

More information

Cardiovascular drugs

Cardiovascular drugs chapter 13 Cardiovascular drugs Cardiovascular drugs act on the heart or blood vessels to control the cardiovascular system. They are used to treat a variety of conditions from hypertension to chronic

More information

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension

More information

Amlodipine plus Lisinopril Tablets AMLOPRES-L

Amlodipine plus Lisinopril Tablets AMLOPRES-L Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)

More information

Angina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room

Angina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University

More information

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided

More information

Blood pressure (BP) control. Hypertension

Blood pressure (BP) control. Hypertension Blood pressure (BP) control Normal heart function Blood pressure (BP) control blood pressure (BP) cardiac output (CO) = total peripheral resistance (TPR) heart rate (HR) filling pressure arteriolar volume

More information

PRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T

PRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in

More information

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have

More information

ANTIHYPERTENSIVE DRUGS

ANTIHYPERTENSIVE DRUGS ANTIHYPERTENSIVE DRUGS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: September 28, 2010 Materials on: Exam #3 Required reading: Katzung, Chapter 11 1 1 in 3 adults HYPERTENSION 64% of

More information

Management of Hypertension. Ahmed El Hawary MD Suez Canal University

Management of Hypertension. Ahmed El Hawary MD Suez Canal University Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and

More information

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut ANTIHYPERTENSIVES Assoc. Prof. Bilgen Başgut Hypertension Hypertension is a condition in which the blood pressure is persistently higher than normal Hypertension > 140 mmhg > 90 mmhg Systolic Blood Pressure

More information

New classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100

New classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100 Hypertension 1 Definition Hypertension can be defined as a condition where blood pressure is elevated to an extent that clinical benefit is obtained from blood pressure lowering. it is an important risk

More information

Cardiovascular Clinical Practice Guideline Pilot Implementation

Cardiovascular Clinical Practice Guideline Pilot Implementation Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high

More information

Categories of HTN. Overview of Hypertension. Types of Hypertension

Categories of HTN. Overview of Hypertension. Types of Hypertension Categories of HTN Overview of Hypertension Normal SBP 100 Quick review of the Basics: What is

More information

TREATMENT OF HYPERTENSION

TREATMENT OF HYPERTENSION TREATMENT OF HYPERTENSION Aim of treatment BP Goals Main items of treatment Lifestyle modification When to start drug Rx Pharmacological therapy 1. Relief of symptoms 2. Prevention of complications and

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Hypertension Epidemiology 6% of deaths worldwide Defined as any of the following: systolic blood pressure 140 mmhg, diastolic blood pressure 90 mmhg, taking antihypertensive medications Pulse pressure=

More information

LESSON ASSIGNMENT. After completing this lesson you will be able to:

LESSON ASSIGNMENT. After completing this lesson you will be able to: LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 7 Therapeutics III. Antihypertensive Agents. LESSON ASSIGNMENT Paragraphs 7-1--7-12. LESSON OBJECTIVES After completing this lesson you will be able to: 7-1. From

More information

Network Hypertension Algorithm

Network Hypertension Algorithm Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following

More information

Drug Treatment of Ischemic Heart Disease

Drug Treatment of Ischemic Heart Disease Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

M2 TEACHING UNDERSTANDING PHARMACOLOGY

M2 TEACHING UNDERSTANDING PHARMACOLOGY M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To

More information

ANTI- HYPERTENSIVE AGENTS

ANTI- HYPERTENSIVE AGENTS CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure.

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure. Hypertension Hypertension Hypertension is defined as either a sustained systolic blood pressure of greater than 140 mm Hg or a sustained diastolic blood pressure of greater than 90 mm Hg. Hypertension

More information

Hypertension: an overview of recommended treatment John Vann Jones PhD, FRCP

Hypertension: an overview of recommended treatment John Vann Jones PhD, FRCP Drug review Hypertension Hypertension: an overview of recommended treatment John Vann Jones PhD, FRCP Skyline Imaging Ltd Professor Vann Jones provides an overview of the wide range of antihypertensive

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Antihypertensive Drugs. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014

Antihypertensive Drugs. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Antihypertensive Drugs Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Antihypertensive Drugs What is Hypertension: A common, incurable, persistent, but usually

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR: 0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration

More information

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER) MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB

More information

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure? Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,

More information

Drug Treatment of Ischemic Heart Disease

Drug Treatment of Ischemic Heart Disease Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE School of Medicine, The University of Jordan November, 2017 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant

More information

Protocol for Angiotensin converting enzyme inhibitors (ACEIs) poisoning management

Protocol for Angiotensin converting enzyme inhibitors (ACEIs) poisoning management Protocol for Angiotensin converting enzyme inhibitors (ACEIs) poisoning management Category/Use Treatment of hypertension, congestive heart failure (CHF), diabetic nephropathy, and post myocardial infarction

More information

Angiotensin-converting enzyme inhibitor (ACEI)

Angiotensin-converting enzyme inhibitor (ACEI) Aldosterone Alpha1 blockers Alpha 2 blockers Angina pectoris Week Four Terms and Meds to Know In the renin-angiotensin-aldosterone system. Helps regulate sodium, wherever this goes sodium goes in turn

More information

Modern Management of Hypertension: Where Do We Draw the Line?

Modern Management of Hypertension: Where Do We Draw the Line? Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure

More information

Pharmacotherapy of Angina Pectoris

Pharmacotherapy of Angina Pectoris Pharmacotherapy of Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth

More information

DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC

DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC Pharmacotherapy of HTN Rationale for reducing arterial pressure Reduce cardiac output Reduce heart rate Reduce stroke

More information

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park. Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed

More information

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment

More information

Pharmacotherapy of Angina Pectoris

Pharmacotherapy of Angina Pectoris Pharmacotherapy of Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth

More information

LOZAR. Composition Each tablet contains Losartan potassium 50 mg.

LOZAR. Composition Each tablet contains Losartan potassium 50 mg. LOZAR Composition Each tablet contains Losartan potassium 50 mg. Tablets Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is

More information

Cardiovascular Pharmacotherapy

Cardiovascular Pharmacotherapy Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin

More information

Anti-hypertensive agents

Anti-hypertensive agents Anti-hypertensive agents Dr. Pran Kishore Deb Assistant Professor, Pharmaceutical Medicinal Chemistry Faculty of Pharmacy, Philadelphia University-Jordan Email: pdeb@philadelphia.edu.jo Anti-hypertensive

More information

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea) Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types

More information